Mission & Topics * Membership Information & How to Join * Terms & Conditions
Archive of Past Roundtable Discussions

2006 Pharma Trends

Date: Thursday, 12 January 2006
Time: 4:30 PM Eastern Time

Background:
The end of one year and the beginning of the new is the time of the year when we all look into our crystal balls and try to come up with predictions for the new year. In December, 2005, for example, Pharmaceutical Executive Magazine published their 2006 Forecast based on interviews with a few experts.

This Roundtable discussion forcused on the top most likely trends as revealed by “Pharma Marketing Network’s 2006 Pharma Trend Survey.” (See below.)

Trends considered include:

  • Increased Focus on Licensing & Acquisition
  • Increased Sales Growth in Specialty Drugs
  • Increase in Regulations of DTC by FDA
  • Decreasing Brand Differentiation
  • Increase in Drug Recalls
  • Increase in Investment (as % of sales) in R&D
  • Decreased Sales Growth (generally; Global)
  • Cuts in DTC Ad Spending

Moderator: John Mack

Participants:

Survey:
See the results of the Pharma Marketing Network’s 2006 Pharma Trend Survey, which asked respondents to rate the likelihood of various trends related to pharmaceutical marketing unfolding in 2006.

Article:
Pharma Trends to Watch in 2006 This is the time of the year when we all look into our crystal balls and try to come up with predictions for the new year. In December, 2005, for example, Pharmaceutical Executive Magazine published their 2006 Forecast based on interviews with a few experts. Pharma Marketing News also hosted its 2006 Pharma Trend Survey online beginning January 9, 2006. The Pharma Marketing Roundtable met by conference call on January 12 to discuss trends as well. This article summarizes the collective wisdom from these sources.

Topics covered include:

  • Survey Topline Results
  • Increase in Generic Competition
  • Brands Caving-In to Generic Onslaught?
  • Brand Differentiation
  • R&D and the Pipeline of New Drugs
  • Dreaded Precautionary Principle
  • FDA Regulation of DTC: To Be or Not To Be?
  • Risk: I Say Relative, You Say Absolute
  • New Directions Part 1: Alternative Media
  • New Directions Part 2: Unbranded DTC